The estimated Net Worth of Barbara Gayle Duncan is at least $583 Tysiąc dollars as of 16 June 2024. Ms. Duncan owns over 33,150 units of Jounce Therapeutics Inc stock worth over $62,322 and over the last 12 years he sold JNCE stock worth over $423,887. In addition, he makes $96,304 as Independent Director at Jounce Therapeutics Inc.
Barbara has made over 22 trades of the Jounce Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 33,150 units of JNCE stock worth $62,322 on 16 June 2024.
The largest trade he's ever made was buying 59,524 units of Jounce Therapeutics Inc stock on 17 October 2017 worth over $75,000. On average, Barbara trades about 3,307 units every 50 days since 2012. As of 16 June 2024 he still owns at least 33,150 units of Jounce Therapeutics Inc stock.
You can see the complete history of Ms. Duncan stock trades at the bottom of the page.
Dr. Barbara G. Duncan serves as Independent Director of the Company. Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc., a public biopharmaceutical company, from 2009 to June 2016 and as treasurer from 2010 to September 2016. She has served on the board of directors of Adaptimmune Therapeutics plc since June 2016, Immunomedics, Inc. since March 2019, ObsEva SA since December 2016, Ovid Therapeutics, Inc. since June 2017, Aevi Genomic Medicine, Inc. (formerly Medgenics, Inc.) from June 2015 to February 2020 and Innoviva, Inc. from September 2016 to April 2018, each of which is a public therapeutics company. Ms. Duncan holds an M.B.A. from the Wharton School of Business and a B.S. from Louisiana State University.
As the Independent Director of Jounce Therapeutics Inc, the total compensation of Barbara Duncan at Jounce Therapeutics Inc is $96,304. There are 9 executives at Jounce Therapeutics Inc getting paid more, with Kimberlee Drapkin having the highest compensation of $2,032,250.
Barbara Duncan is 55, he's been the Independent Director of Jounce Therapeutics Inc since 2016. There are 10 older and 4 younger executives at Jounce Therapeutics Inc. The oldest executive at Jounce Therapeutics Inc is Dr. Louis M. Weiner M.D., 69, who is the Founder.
Barbara's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.
Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca... oraz Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Jounce Therapeutics Inc executives and other stock owners filed with the SEC include: